John W. Huggins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John W. Huggins has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Ann C. Gessaman
Antiviral Program, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah U.S.A.
1 shared publication- Ayana Sakurai
Disease Control and Prevention Centre, National Centre for Global Health and Medicine, Tokyo 1628655, Japan
1 shared publication Chris Hartmann
Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter Street, Fort Detrick, MD 21702-5011, USA
1 shared publication- Donald F. Smee
Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA
1 shared publication - Fuminari Miura
Centre for infectious disease control, National institute for public health and the environment (RIVM), Bilthoven, the Netherlands
1 shared publication - Hyeongki Park
School of Biomedical Convergence Engineering, Pusan National University, Yangsan 50612, Republic of Korea
1 shared publication
Latest Publications
- 2 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (805) , eads4773
Modeling lesion transition dynamics to clinically characterize patients with clade I mpox in the Democratic Republic of the Congo
Coinciding with the global outbreak of clade IIb mpox virus (MPXV), the Democratic Republic of the Congo (DRC) recently experienced a rapid surge in mpox cases with clade I MPXV. On 14 August 2024, the World Health Organization declared the continued cross-border spread of this clade in Africa a public health emergency of international concern (PHEIC). Clade I MPXV is known to be more fatal than clade IIb, but its clinical characteristics and prognosis differ between patients. Here, we used mathematical modeling to quantify temporal changes in total lesion counts during clade I MPXV infections, using data from a large cohort of patients with mpox in the DRC from 2007 to 2011. We further analyzed individuals’ clinical data to explore predictive biomarkers of high lesion counts. Our analysis indicates that patients with clade I mpox can be stratified into two groups according to lesion severity and that viral load in peripheral blood at symptom onset may serve as a predictor for this classification [area under the curve (AUC) = 0.70]. Our estimates also suggest substantial individual heterogeneity in the time period during which patients have lesions, ranging from 20 to 65 days. Understanding the severity and duration of lesions in different patients, as characterized by our approach, may contribute to more tailored treatment strategies and control measures in ongoing clade I mpox outbreaks.
- 2 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (805) , eads4773
Modeling lesion transition dynamics to clinically characterize patients with clade I mpox in the Democratic Republic of the Congo
Coinciding with the global outbreak of clade IIb mpox virus (MPXV), the Democratic Republic of the Congo (DRC) recently experienced a rapid surge in mpox cases with clade I MPXV. On 14 August 2024, the World Health Organization declared the continued cross-border spread of this clade in Africa a public health emergency of international concern (PHEIC). Clade I MPXV is known to be more fatal than clade IIb, but its clinical characteristics and prognosis differ between patients. Here, we used mathematical modeling to quantify temporal changes in total lesion counts during clade I MPXV infections, using data from a large cohort of patients with mpox in the DRC from 2007 to 2011. We further analyzed individuals’ clinical data to explore predictive biomarkers of high lesion counts. Our analysis indicates that patients with clade I mpox can be stratified into two groups according to lesion severity and that viral load in peripheral blood at symptom onset may serve as a predictor for this classification [area under the curve (AUC) = 0.70]. Our estimates also suggest substantial individual heterogeneity in the time period during which patients have lesions, ranging from 20 to 65 days. Understanding the severity and duration of lesions in different patients, as characterized by our approach, may contribute to more tailored treatment strategies and control measures in ongoing clade I mpox outbreaks.
- Open Access
- 10 September 2008
- Published by Elsevier in Journal of Virological Methods
- Vol. 153 (2) , 190-195
Dual-probe real-time PCR assay for detection of variola or other orthopoxviruses with dried reagents
- 10 September 2008
- Published by Elsevier in Journal of Virological Methods
- Vol. 153 (2) , 190-195
Open AccessDual-probe real-time PCR assay for detection of variola or other orthopoxviruses with dried reagents
- Open Access
- 15 February 2005
- Published by Elsevier in Antiviral Research
- Vol. 66 (2-3) , 99-102
Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models
- 15 February 2005
- Published by Elsevier in Antiviral Research
- Vol. 66 (2-3) , 99-102
Open AccessInterferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models
- 1 September 1995
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 20 (3) , 197-202
Pharmacokinetics of the antiviral agent 3-deazaneplanocin A
The pharmacokinetics of 3-deazaneplanocin A (c3Nep), a competitive inhibitor of S-adenosyl-l-homocysteine (AdoHcy) hydrolase and novel antiviral agent, was investigated in female BALB/c mice. Animals were given a single intravenous dose of [3H]-c3Nep (0.1 mg/kg: 10 μCi), and blood and selected tissues were collected at various intervals thereafter for up to 72 h. The plasma concentration versus time data for c3Nep was best approximated by a two-compartment open model with first order elimination. The elimination half-life was 12.8 min, the area-under curve (AUC) was 3.38 μg.min.ml−1. The distribution of c3Nep into tissues was not extensive. Following 30, 120 min, and 24 h after dosing, the kidneys and the liver contained the highest amount of drug, but this amount did not exceed 1 μg/g tissue. At these time periods, the majority of activity in the tissues represented labeled derivatives of c3Nep indicating that this compound was converted to stable metabolites. The presence of labeled conversion products in the blood confirmed that this drug is metabolized in vivo. The fact that c3Nep bound to plasma proteins in vitro may explain this drug’s limited tissue distribution. The half-life and tissue distribution of c3Nep were different from those of carbocyclic 3-deazaadenosine, a related adenosine nucleoside antiviral drug and AdoHcy hydrolase inhibitor.
- 1 September 1995
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 20 (3) , 197-202
Pharmacokinetics of the antiviral agent 3-deazaneplanocin A
The pharmacokinetics of 3-deazaneplanocin A (c3Nep), a competitive inhibitor of S-adenosyl-l-homocysteine (AdoHcy) hydrolase and novel antiviral agent, was investigated in female BALB/c mice. Animals were given a single intravenous dose of [3H]-c3Nep (0.1 mg/kg: 10 μCi), and blood and selected tissues were collected at various intervals thereafter for up to 72 h. The plasma concentration versus time data for c3Nep was best approximated by a two-compartment open model with first order elimination. The elimination half-life was 12.8 min, the area-under curve (AUC) was 3.38 μg.min.ml−1. The distribution of c3Nep into tissues was not extensive. Following 30, 120 min, and 24 h after dosing, the kidneys and the liver contained the highest amount of drug, but this amount did not exceed 1 μg/g tissue. At these time periods, the majority of activity in the tissues represented labeled derivatives of c3Nep indicating that this compound was converted to stable metabolites. The presence of labeled conversion products in the blood confirmed that this drug is metabolized in vivo. The fact that c3Nep bound to plasma proteins in vitro may explain this drug’s limited tissue distribution. The half-life and tissue distribution of c3Nep were different from those of carbocyclic 3-deazaadenosine, a related adenosine nucleoside antiviral drug and AdoHcy hydrolase inhibitor.
- Open Access
- 1 March 1991
- Published by Elsevier in Antiviral Research
- Vol. 15 (3) , 229-239
Prophylactic and therapeutic activities of 7-thia-8-oxoguanosine against Punta Toro virus infections in mice
- 1 March 1991
- Published by Elsevier in Antiviral Research
- Vol. 15 (3) , 229-239
Open AccessProphylactic and therapeutic activities of 7-thia-8-oxoguanosine against Punta Toro virus infections in mice